Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 11/20 | 0.69 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.40 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3168885 | 0.94 | PTGDR2 (0.73) | PTGDR2PTGDRALDH1A1CYSLTR2CYSLTR1 | |
| SCHEMBL3169535 | 0.93 | PTGDR2 (0.72) | PTGDR2PTGDRALDH1A1CYSLTR2CYSLTR1 | |
| SCHEMBL3173348 | 0.89 | PTGDR2 (0.60) | PTGDR2PTGDRCYSLTR2CYSLTR1 | |
| SCHEMBL12678564 | 0.89 | PTGDR2 (0.82) | PTGDR2PTGDRCYSLTR2CYSLTR1 | |
| SCHEMBL3176927 | 0.88 | PTGDR2 (0.73) | PTGDR2PTGDR | |
| SCHEMBL3174351 | 0.83 | PTGDR2 (0.58) | PTGDR2PTGDRCYSLTR2CYSLTR1 | |
| SCHEMBL3180426 | 0.82 | PTGDR2 (0.68) | PTGDR2PTGDRALDH1A1CYSLTR2CYSLTR1 | |
| SCHEMBL3159452 | 0.81 | PTGDR2 (0.72) | PTGDR2PTGDRALDH1A1 | |
| SCHEMBL3180249 | 0.81 | PTGDR2 (1.00) | PTGDR2PTGDRCYSLTR2CYSLTR1 | |
| SCHEMBL3159691 | 0.79 | PTGDR2 (0.90) | PTGDR2PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273745-B2 | Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents | ASTELLAS PHARMA INC (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273745-B2 | Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents | ASTELLAS PHARMA INC (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273745-B2 | Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents | ASTELLAS PHARMA INC (JP) | 2012-09-25 | — | — | US | disclosed |
| EP-2094662-B1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC (JP) | 2012-04-11 | — | — | EP | disclosed |
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | HRH2, HRH1, HRH4 | PTGDR2 116/4885PTGDR 189/4885ALDH1A1 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.